Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Baxalta Submits Marketing Authorization Application to the European Medicines Agency for ADYNOVI for Treatment of Hemophilia A Patients

Source Link:: http://newsroom.baxalta.com/press-releases/press-release-details/2016/Baxalta-Submits-Marketing-Authorization-Application-to-the-European-Medicines-Agency-for-ADYNOVI-for-Treatment-of-Hemophilia-A-Patients/default.aspx

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

BXLT

Community voting in process

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details

ADYNOVI is built on ADVATE [Antihemophilic Factor (Recombinant)], the world's most prescribed FVIII treatment with more than 12 years of patient experience worldwide

Currently marketed in the U.S. as ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], ADYNOVI is an innovative recombinant Factor VIII treatment designed to offer simple, twice-weekly dosing

Baxalta remains committed to bringing new innovative treatments to the hemophilia community, providing options for personalized care

http://newsroom.baxa...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Mar 02, 2016

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Adynovi, Advate, Recombinant, Hemophilia, Pegylated, Hemophilia A